Phylogica Limited
PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on … Read more
Phylogica Limited (PH7) - Total Assets
Latest total assets as of June 2025: €183.28 Million EUR
Based on the latest financial reports, Phylogica Limited (PH7) holds total assets worth €183.28 Million EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Phylogica Limited - Total Assets Trend (2016–2025)
This chart illustrates how Phylogica Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Phylogica Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Phylogica Limited's total assets of €183.28 Million consist of 96.9% current assets and 3.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 83.5% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.85 Million | 2.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Phylogica Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Phylogica Limited's current assets represent 96.9% of total assets in 2025, a decrease from 99.1% in 2016.
- Cash Position: Cash and equivalents constituted 83.5% of total assets in 2025, down from 97.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 2.1% of total assets.
Phylogica Limited Competitors by Total Assets
Key competitors of Phylogica Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Phylogica Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Phylogica Limited generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Phylogica Limited is currently not profitable relative to its asset base.
Phylogica Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.41 | 9.40 | 35.80 |
| Quick Ratio | 14.41 | 9.40 | 35.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €165.21 Million | € 76.51 Million | € 24.56 Million |
Phylogica Limited - Advanced Valuation Insights
This section examines the relationship between Phylogica Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.47 |
| Latest Market Cap to Assets Ratio | 1.59 |
| Asset Growth Rate (YoY) | 100.9% |
| Total Assets | €183.28 Million |
| Market Capitalization | $291.84 Million USD |
Valuation Analysis
Above Book Valuation: The market values Phylogica Limited's assets above their book value (1.59 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Phylogica Limited's assets grew by 100.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Phylogica Limited (2016–2025)
The table below shows the annual total assets of Phylogica Limited from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €183.28 Million | +100.88% |
| 2024-06-30 | €91.24 Million | +145.49% |
| 2023-06-30 | €37.17 Million | -18.05% |
| 2022-06-30 | €45.35 Million | -21.73% |
| 2021-06-30 | €57.94 Million | +83.67% |
| 2020-06-30 | €31.55 Million | +370.75% |
| 2019-06-30 | €6.70 Million | +96.00% |
| 2018-06-30 | €3.42 Million | -66.96% |
| 2017-06-30 | €10.35 Million | +42.42% |
| 2016-06-30 | €7.27 Million | -- |